2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Artal International S.C.A. | 10% Owner | 11,259,438 | Oct 16, 2023 |
| Artal International Management S.A. | 10% Owner | 11,259,438 | Oct 16, 2023 |
| Artal Group S.A. | 10% Owner | 11,259,438 | Oct 16, 2023 |
| Westend S.A. | 10% Owner | 11,259,438 | Oct 16, 2023 |
| Stichting Administratiekantoor Westend | 10% Owner | 11,259,438 | Oct 16, 2023 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | Feb 25, 2026 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 28.8 | -8,484 | -7.93% | ✓ | $399.4K |
| Feb 17, 2026 | Feb 19, 2026 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 42.5 | -4,157 | -3.19% | ✗ | $193.4K |
| Feb 17, 2026 | Feb 19, 2026 | Ho Junlin | GENERAL COUNSEL | Sell | 40.0 | -9,580 | -3.81% | ✗ | $445.7K |
| Feb 17, 2026 | Feb 19, 2026 | Parlavecchio Caryn | CHRO | Sell | 40.0 | -9,035 | -5.07% | ✗ | $420.4K |
| Feb 17, 2026 | Feb 19, 2026 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 40.0 | -7,989 | -6.95% | ✗ | $371.7K |
| Feb 9, 2026 | Feb 11, 2026 | Vaishnaw Akshay | President | Neutral | 85.0 | +47,021 | 7.89% | ✗ | - |
| Feb 9, 2026 | Feb 11, 2026 | Sinha Vikas | CFO | Neutral | 85.0 | +47,021 | 8.06% | ✗ | - |
| Feb 9, 2026 | Feb 11, 2026 | Qatanani Mo | Chief Scientific Officer | Neutral | 90.0 | +29,258 | 34.16% | ✗ | - |
| Feb 9, 2026 | Feb 11, 2026 | Parlavecchio Caryn | Chief Human Resources Officer | Neutral | 90.0 | +29,258 | 19.65% | ✗ | - |
| Feb 9, 2026 | Feb 11, 2026 | Marantz Jing L. | Chief Medical Officer | Neutral | 90.0 | +34,482 | 36.04% | ✗ | - |
| Feb 9, 2026 | Feb 11, 2026 | Ho Junlin | General Counsel | Neutral | 90.0 | +36,572 | 17.05% | ✗ | - |
| Feb 9, 2026 | Feb 11, 2026 | Hallal David | CEO | Neutral | 85.0 | +128,004 | 7.33% | ✗ | - |
| Feb 9, 2026 | Feb 11, 2026 | Woods Keith | COO | Neutral | 85.0 | +47,021 | 8.06% | ✗ | - |
| Dec 11, 2025 | Feb 6, 2026 | Invus Global Management, LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 22, 2026 | Jan 23, 2026 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 25.0 | -14,898 | -14.82% | ✓ | $695.9K |
| Jan 16, 2026 | Jan 21, 2026 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 40.0 | -8,406 | -7.71% | ✗ | $373.9K |
| Jan 16, 2026 | Jan 21, 2026 | Parlavecchio Caryn | CHRO | Sell | 40.0 | -6,600 | -4.25% | ✗ | $293.6K |
| Jan 16, 2026 | Jan 21, 2026 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 40.0 | -5,798 | -5.71% | ✗ | $257.9K |
| Jan 16, 2026 | Jan 21, 2026 | Ho Junlin | GENERAL COUNSEL | Sell | 40.0 | -8,016 | -3.60% | ✗ | $356.5K |
| Jan 14, 2026 | Jan 16, 2026 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 25.0 | -13,112 | -10.74% | ✓ | $592.6K |
| Jan 13, 2026 | Jan 15, 2026 | Sinha Vikas | CFO | Sell | 40.0 | -16,755 | -2.79% | ✗ | $715.4K |
| Jan 13, 2026 | Jan 15, 2026 | Woods Keith | COO | Sell | 40.0 | -16,746 | -2.79% | ✗ | $715.1K |
| Jan 13, 2026 | Jan 15, 2026 | Vaishnaw Akshay | President | Sell | 40.0 | -20,438 | -3.32% | ✗ | $872.7K |
| Jan 13, 2026 | Jan 15, 2026 | Hallal David | CEO | Sell | 37.5 | -57,450 | -3.18% | ✗ | $2.5M |
| Dec 16, 2025 | Dec 18, 2025 | Peng Katie | Director | Sell | 26.3 | -1,006 | -2.97% | ✗ | $44.4K |
| Oct 7, 2025 | Dec 16, 2025 | AKKARAJU SRINIVAS | Director | Buy | 95.0 | +29,599 | 5.67% | ✗ | $1.2M |
| Dec 4, 2025 | Dec 5, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 3.8 | -136,462 | -55.60% | ✓ | $6.2M |
| Oct 8, 2025 | Oct 9, 2025 | Hallal David | CEO | Neutral | 27.5 | -205,000 | -10.20% | ✗ | - |
| Oct 3, 2025 | Oct 7, 2025 | AKKARAJU SRINIVAS | Director | Buy | 97.5 | +500,439 | 9.40% | ✗ | $18.8M |
| Sep 22, 2025 | Sep 24, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 41.3 | -3,353 | -2.99% | ✓ | $102.8K |
| Sep 16, 2025 | Sep 17, 2025 | Peng Katie | Director | Sell | 45.0 | -1,006 | -2.88% | ✓ | $32.7K |
| Sep 16, 2025 | Sep 17, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 42.5 | -3,178 | -2.75% | ✗ | $106.5K |
| Aug 18, 2025 | Aug 19, 2025 | Parlavecchio Caryn | CHRO | Sell | 42.5 | -2,178 | -1.38% | ✗ | $67.9K |
| Jul 16, 2025 | Jul 18, 2025 | FLIER JEFFREY S. | Director | Sell | 7.5 | -11,136 | -31.63% | ✓ | $445.7K |
| Jul 8, 2025 | Jul 10, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 17.5 | -24,066 | -17.24% | ✓ | $828.9K |
| Jun 23, 2025 | Jun 25, 2025 | FLIER JEFFREY S. | Director | Sell | 5.0 | -31,452 | -47.18% | ✓ | $1M |
| Jun 16, 2025 | Jun 17, 2025 | Peng Katie | Director | Sell | 28.8 | -3,031 | -7.99% | ✓ | $96.9K |
| Jun 16, 2025 | Jun 17, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 42.5 | -3,668 | -2.56% | ✗ | $117.4K |
| Jun 16, 2025 | Jun 17, 2025 | Parlavecchio Caryn | CHRO | Sell | 42.5 | -6,186 | -3.78% | ✗ | $198K |
| Jun 16, 2025 | Jun 17, 2025 | Ho Junlin | GENERAL COUNSEL | Sell | 42.5 | -7,442 | -3.24% | ✗ | $238.2K |
| Jun 9, 2025 | Jun 11, 2025 | Ho Junlin | GENERAL COUNSEL | Neutral | 82.5 | +8,571 | 3.87% | ✗ | - |
| May 29, 2025 | May 30, 2025 | FLIER JEFFREY S. | Director | Sell | 25.0 | -6,075 | -11.59% | ✓ | $180.6K |
| May 29, 2025 | May 30, 2025 | Burow Kristina | Director | Sell | 50.0 | -5,400 | -0.23% | ✓ | $160.5K |
| May 29, 2025 | May 30, 2025 | Gilman Michael | Director | Sell | 32.5 | -3,375 | -5.76% | ✓ | $100.3K |
| May 29, 2025 | May 30, 2025 | Brudnick Richard | Director | Sell | 10.0 | -6,075 | -28.75% | ✓ | $180.5K |
| May 29, 2025 | May 30, 2025 | Reed Joshua | Director | Sell | 10.0 | -5,400 | -25.55% | ✓ | $160.5K |
| May 29, 2025 | May 30, 2025 | Vaishnaw Akshay | President | Sell | 45.0 | -6,750 | -1.08% | ✓ | $200.6K |
| May 22, 2025 | May 23, 2025 | Brudnick Richard | Director | Neutral | 90.0 | +7,632 | 56.53% | ✗ | - |
| May 22, 2025 | May 23, 2025 | Reed Joshua | Director | Neutral | 90.0 | +7,632 | 56.53% | ✗ | - |
| May 22, 2025 | May 23, 2025 | Burow Kristina | Director | Neutral | 60.0 | +7,632 | 0.32% | ✗ | - |
| May 22, 2025 | May 23, 2025 | AKKARAJU SRINIVAS | Director | Neutral | 55.0 | +7,632 | 0.14% | ✗ | - |
| May 22, 2025 | May 23, 2025 | Peng Katie | Director | Neutral | 90.0 | +7,632 | 25.17% | ✗ | - |
| May 22, 2025 | May 23, 2025 | Gilman Michael | Director | Neutral | 90.0 | +7,632 | 14.98% | ✗ | - |
| May 22, 2025 | May 23, 2025 | FLIER JEFFREY S. | Director | Neutral | 90.0 | +7,632 | 17.04% | ✗ | - |
| May 2, 2025 | May 6, 2025 | Woods Keith | COO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 2, 2025 | May 6, 2025 | Vaishnaw Akshay | President | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 2, 2025 | May 6, 2025 | Sinha Vikas | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 2, 2025 | May 6, 2025 | Hallal David | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 27, 2025 | Apr 29, 2025 | Woods Keith | COO | Neutral | 90.0 | +600,000 | 100.00% | ✗ | - |
| Apr 27, 2025 | Apr 29, 2025 | Vaishnaw Akshay | President | Neutral | 90.0 | +600,000 | 2613.81% | ✗ | - |
| Apr 27, 2025 | Apr 29, 2025 | Hallal David | CEO | Neutral | 90.0 | +1,500,000 | 493.27% | ✗ | - |
| Apr 27, 2025 | Apr 29, 2025 | Sinha Vikas | CFO | Neutral | 90.0 | +600,000 | 100.00% | ✗ | - |
| Apr 25, 2025 | Apr 29, 2025 | Sacco Tracey | Chief Commercial Officer | Sell | 32.5 | -5,000 | -6.51% | ✓ | $164.1K |
| Apr 29, 2025 | Woods Keith | COO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Apr 29, 2025 | Sinha Vikas | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Mar 24, 2025 | Mar 25, 2025 | Sacco Tracey | Chief Commercial Officer | Sell | 28.8 | -6,500 | -8.31% | ✓ | $215K |
| Mar 24, 2025 | Mar 25, 2025 | Moore Erin | Interim PFO and PAO | Sell | 22.5 | -13,564 | -14.10% | ✓ | $449.2K |
| Mar 21, 2025 | Moore Erin | Interim PFO and PAO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Mar 17, 2025 | Mar 19, 2025 | Peng Katie | Director | Sell | 41.3 | -1,006 | -3.21% | ✓ | $34.6K |
| Mar 10, 2025 | Mar 12, 2025 | Myles Edward H | CFO | Sell | 3.8 | -142,292 | -56.10% | ✓ | $5.1M |
| Mar 10, 2025 | Mar 12, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Neutral | 90.0 | +32,145 | 28.94% | ✗ | - |
| Mar 10, 2025 | Mar 12, 2025 | Parlavecchio Caryn | CHRO | Neutral | 90.0 | +23,570 | 16.80% | ✗ | - |
| Mar 10, 2025 | Mar 12, 2025 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Neutral | 90.0 | +34,285 | 51.02% | ✗ | - |
| Mar 10, 2025 | Mar 12, 2025 | Backstrom Jay T. | CEO | Neutral | 90.0 | +113,570 | 36.40% | ✗ | - |
| Mar 10, 2025 | Mar 12, 2025 | Ho Junlin | GENERAL COUNSEL | Neutral | 90.0 | +32,145 | 16.98% | ✗ | - |
| Mar 10, 2025 | Mar 12, 2025 | Sacco Tracey | Chief Commercial Officer | Neutral | 90.0 | +27,855 | 61.36% | ✗ | - |
| Feb 18, 2025 | Feb 20, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 20.0 | -72,645 | -12.40% | ✓ | $2.7M |
| Feb 18, 2025 | Feb 20, 2025 | Parlavecchio Caryn | CHRO | Sell | 42.5 | -5,296 | -3.64% | ✗ | $195K |
| Feb 18, 2025 | Feb 20, 2025 | Myles Edward H | CFO | Sell | 40.0 | -7,809 | -5.26% | ✗ | $287.6K |
| Feb 18, 2025 | Feb 20, 2025 | Ho Junlin | GENERAL COUNSEL | Sell | 42.5 | -5,742 | -2.94% | ✗ | $211.5K |
| Feb 18, 2025 | Feb 20, 2025 | Backstrom Jay T. | CEO | Sell | 40.0 | -18,372 | -5.56% | ✗ | $676.6K |
| Jan 16, 2025 | Jan 21, 2025 | Backstrom Jay T. | CEO | Sell | 40.0 | -22,308 | -6.33% | ✗ | $986K |
| Jan 16, 2025 | Jan 21, 2025 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 42.5 | -5,655 | -7.76% | ✗ | $249.9K |
| Jan 16, 2025 | Jan 21, 2025 | Sacco Tracey | Chief Commercial Officer | Sell | 42.5 | -3,890 | -7.89% | ✗ | $171.9K |
| Jan 16, 2025 | Jan 21, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 40.0 | -7,347 | -5.15% | ✗ | $324.7K |
| Jan 16, 2025 | Jan 21, 2025 | Parlavecchio Caryn | CHRO | Sell | 40.0 | -6,434 | -4.23% | ✗ | $284.4K |
| Jan 16, 2025 | Jan 21, 2025 | Myles Edward H | CFO | Sell | 40.0 | -12,539 | -7.78% | ✗ | $554.2K |
| Jan 16, 2025 | Jan 21, 2025 | Ho Junlin | GENERAL COUNSEL | Sell | 40.0 | -9,039 | -4.43% | ✗ | $399.5K |
| Dec 10, 2024 | Dec 12, 2024 | Invus Public Equities, L.P. | 10% Owner | Sell | 15.0 | -1,600,000 | -14.75% | ✗ | $66.6M |
| Nov 25, 2024 | Nov 27, 2024 | Invus Public Equities, L.P. | 10% Owner | Sell | 15.0 | -409,433 | -3.64% | ✗ | $15.8M |
| Nov 22, 2024 | Nov 26, 2024 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 38.8 | -8,520 | -2.23% | ✓ | $315.8K |
| Nov 12, 2024 | Nov 13, 2024 | Gilman Michael | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 11, 2024 | Nov 13, 2024 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 41.3 | -2,105 | -2.81% | ✓ | $63.2K |
| Oct 8, 2024 | Oct 10, 2024 | Myles Edward H | CFO | Sell | 15.0 | -37,187 | -18.76% | ✓ | $1.3M |
| Oct 7, 2024 | Oct 7, 2024 | Myles Edward H | CFO | Sell | 3.8 | -206,240 | -56.15% | ✓ | $5.5M |
| Oct 7, 2024 | Oct 7, 2024 | Sacco Tracey | CHIEF COMMERCIAL OFFICER | Sell | 7.5 | -30,000 | -37.84% | ✓ | $768.7K |
| Oct 7, 2024 | Oct 7, 2024 | AKKARAJU SRINIVAS | Director | Sell | 21.3 | -1,175,713 | -8.99% | ✓ | $34.4M |
| Oct 7, 2024 | Oct 7, 2024 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 5.0 | -109,375 | -60.02% | ✓ | $3M |
| Sep 16, 2024 | Sep 19, 2024 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 46.3 | -1,936 | -1.34% | ✗ | $16.6K |
| Aug 16, 2024 | Aug 19, 2024 | Parlavecchio Caryn | CHRO | Sell | 48.8 | -1,451 | -0.95% | ✗ | $13.5K |